Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations

NCT00891579 is registered in ClinicalTrials.gov with Chinese Society of Lung Cancer as lead sponsor.

NCT NCT00891579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00891579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations
Lead sponsor
Chinese Society of Lung Cancer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
November 30, 2012
Enrollment
161 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer